Ascendis Pharma Says FDA Granted Orphan Drug Exclusivity To YORVIPATH For Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma Says FDA Granted Orphan Drug Exclusivity To YORVIPATH For Treatment Of Hypoparathyroidism In Adults
Ascendis Pharma表示，FDA授予YORVIPATH孤兒藥品獨家權，用於成人甲狀旁腺功能減退症的治療。
YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period.
YORVIPATH是甲狀旁腺激素（PTH [1-34]）的前藥，每天給藥一次，旨在在24小時給藥期內持續暴露於釋放的甲狀旁腺激素。
Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of parathyroid hormone that impact multiple organs and affects an estimated 70,000 to 90,000 people in the United States.
甲狀旁腺功能減退是一種罕見的內分泌疾病，由甲狀旁腺激素水平不足引起，會影響多個器官，在美國估計有70,000至90,000人受到影響。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間